← Back to All Calculators
Absolute Neutrophil Count (ANC)
Hematology / Oncology
The ANC measures the absolute number of neutrophils in the blood and is a critical marker of infection susceptibility, particularly in oncology patients receiving chemotherapy. Values below 500 cells/µL define severe neutropenia with high febrile neutropenia risk.
Method 1: Total Neutrophils %
Method 2: Segs + Bands %
Reference
| ANC (cells/µL) | Category | Clinical Implication |
|---|---|---|
| ≥1500 | Normal | Routine care |
| 1000–1499 | Mild Neutropenia | Monitor closely |
| 500–999 | Moderate Neutropenia | Elevated infection risk |
| 100–499 | Severe Neutropenia | High febrile neutropenia risk |
| <100 | Profound Neutropenia | Protective isolation required |
Formula
ANC = WBC × (Neutrophils% / 100) × 1000
or
ANC = WBC × [(Segs% + Bands%) / 100] × 1000
or
ANC = WBC × [(Segs% + Bands%) / 100] × 1000
Clinical Notes
Febrile neutropenia definition: ANC <500 cells/µL + fever ≥38.3°C (single) or ≥38.0°C sustained >1 hour.
Chemotherapy nadir: Typically 7–14 days post-treatment; recovery by 21–28 days in most regimens.
MASCC score is used for febrile neutropenia risk stratification to determine outpatient vs. inpatient management eligibility.
G-CSF (filgrastim/pegfilgrastim) use for prophylaxis is indicated when febrile neutropenia risk exceeds 20% based on regimen and patient factors.
Chemotherapy nadir: Typically 7–14 days post-treatment; recovery by 21–28 days in most regimens.
MASCC score is used for febrile neutropenia risk stratification to determine outpatient vs. inpatient management eligibility.
G-CSF (filgrastim/pegfilgrastim) use for prophylaxis is indicated when febrile neutropenia risk exceeds 20% based on regimen and patient factors.
For educational use only. Clinical decisions must incorporate full patient evaluation.
